November 2024 - BioMedWire (BMW)

TuesdayNov 26, 2024 10:00 am

MS Drug Could Counter Poor Working Memory

A new study has determined that a medication normally prescribed for multiple sclerosis can help persons with poor working memory. Working memory is an important component of cognitive function. Sadly, it is often impaired in patients with conditions like schizophrenia. The study was led by University of Basel’s Professors Dominique de Quervain and Andreas Papassotiropoulos. For their randomized and double-blind study, the researchers tested the efficacy of fampridine on the working memory of forty-three healthy adults. Fampridine, the medication in question, is normally used to enhance walking ability for patients with multiple sclerosis. Patients with this chronic illness often experience…

MondayNov 25, 2024 8:45 am

Kairos Pharma Ltd. (NYSE: KAPA) Developing Innovative Therapies to Tackle Cancer Drug Resistance, Immune Suppression

The company has an extensive IP portfolio, valid through 2040, and a drug pipeline in different preclinical and clinical stages, targeting cancer drug resistance and immune suppression. Kairos Pharma’s lead candidate ENV-105 is an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer (NCT05534646, in combination with Apalutamide) and a Phase 1 trial for EGFR-driven non-small cell lung cancer (NCT05401110, in combination with Osimertinib). The company is working with PreCheck Health Services to develop companion biomarkers for ENV-105, with the aim of…

FridayNov 22, 2024 10:00 am

Could a Medicare Special Needs Plan Be Right for You?

A Special Needs Plan (SNP) customizes medical benefits for individuals who have chronic illnesses, are on Medicaid, or live in specific institutions. SNPs are offered under Medicare Advantage, with figures showing that enrollees under this plan may hit 28% by next year. What should you know about SNPs? They cover hospital care (Part A), physician visits and some other charges (Part B) and prescription drugs (Part D). There are three kinds of SNPs; Chronic condition SNPs These plans cover patients with disabling or severe chronic diseases like diabetes, stroke, chronic heart failure, and cancer. Dual-eligible SNPs This covers individuals eligible…

FridayNov 22, 2024 8:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Shares Data Supporting Innovative Proprietary Systemic Antitumor Platform

“In 2024, over 611,000 deaths from cancer are projected for the U.S.,” the ACA reported. “That’s more than 1,600 deaths from cancer each day.” Calidi Biotherapeutics’ RTNova (“CLD-400”) is an innovative systemic antitumor enveloped virotherapy, designed to unlock new possibilities in cancer therapy. RTNova offers a systemic approach that enables providers to target and treat metastatic tumors that were previously untouchable. The American Cancer Society (“ACA”) has projected that 2024 will be the first year ever to see two million people diagnosed with cancer, which remains the second leading cause of death in the United States, after heart disease (https://ibn.fm/ADo2Q).…

ThursdayNov 21, 2024 10:00 am

Research Suggests Cancer Survivors are Less Prone to Alzheimer’s Development

Alzheimer’s and cancer are common diagnoses, especially among older individuals. Prior research has observed an inverse association between both conditions, with a separate study also finding that survivors of cancer have a lower risk of developing Alzheimer’s in comparison to individuals without a history of cancer. Now new research has uncovered evidence of a lower prevalence of dementia following a patient’s cancer diagnosis. The research was carried out by scientists at Imperial College, who focused on health data of over three million individuals aged 60 and above. The scientists performed genetic analyzes on hundreds of genes, finding a genetic profile…

TuesdayNov 19, 2024 10:00 am

New Drug Approach Could Roll Back Pancreatic Cancer Immunotherapy Resistance

New research by scientists from the Oregon Health & Science University and Johns Hopkins Kimmel Cancer Center has found a new approach that can make tumors resistant to immunotherapy vulnerable to the treatment. For their study, the researchers evaluated the effectiveness and safety of the combination of 2 medications; entinostat, an epigenetic drug; and nivolumab, an immunotherapy medication. The drugs were administered to a group of twenty-seven patients with advanced pancreatic ductal adenocarcinoma. The patients had in the past undergone chemotherapy. The immune activity in the microenvironment of patients with this common type of pancreatic cancer is suppressed, which allows…

FridayNov 15, 2024 10:00 am

Study Finds That Pollution Increases Autism Risk

Autism spectrum disorder is a developmental and neurological disorder that affects how an individual communicates with others, interacts with them, behaves and learns. About 75 million individuals globally live with this disorder, which is about 1% of the global population. The disorder’s symptoms usually manifest in the first 2 years of an infant’s life, with common symptoms including repetitive behaviors and restricted interests. Various studies suggest that having older parents, having an older sibling with autism, having a very low birth weight, and having genetic conditions like Down syndrome heighten the likelihood of a child developing autism. Now a new…

ThursdayNov 14, 2024 10:00 am

How e-Commerce Deliveries Can Be Speeded Up

It is common knowledge that fast delivery for e-commerce businesses plays a big role in whether customers have a positive or negative experience. Latest figures show that 63% of online shoppers expect expedited delivery always, which eliminates any room for delay. Over 90% of consumers also consider same-day shipping as the standard. With consumer expectations increasing, businesses need to ensure that their products arrive even faster or risk losing consumers to competitors who prioritize efficient and fast shipping. Data shows that businesses which provide the option for same-day delivery perform better than 85% of their competitors. Enhancing consumer satisfaction also…

WednesdayNov 13, 2024 8:45 am

Annovis Bio Inc. (NYSE: ANVS) Concludes Q3 with Strategic Milestones and FDA-Cleared Phase 3 Program for Alzheimer’s Disease

Annovis provided business and financial updates for Q3 2024, spotlighting progress toward pivotal buntanetap trials in Alzheimer’s disease. The FDA has cleared Annovis to proceed with a Phase 3 program, which will include a 6-month study to confirm buntanetap’s symptomatic benefits (beginning Q1 2025) and an 18-month study to explore potential disease-modifying effects. Matthew Peterson, Ph.D., was appointed as Senior Clinical Scientist and will oversee quality and rigor in upcoming clinical trials. Annovis filed three new patents for innovative combination therapies, involving buntanetap with Trulicity (dulaglutide), Viagra (sildenafil), and a combination of all three. As of Nov. 8, 2024, the…

TuesdayNov 12, 2024 10:00 am

Data Captured by Period-Tracking Apps isn’t Protected by HIPAA

Last week, Donald Trump was elected the 47th president of the United States. Soon after, a post on X warning that personal data shared on pregnancy and menstrual cycle tracking applications could be used against individuals who sought abortions in the country went viral. The post, which had more than 10 million views, advised that users immediately stop using the applications and delete them. When the Supreme Court overturned Roe v. Wade in June 2022, similar warnings were shared online. These warnings also raise questions on whether private health data from period-tracking applications is covered under the Health Insurance Portability…